Perspectives for the development of human papillomavirus vaccines and immunotherapy.
Human papillomavirus (HPV) is the most common sexually transmitted infection and is responsible for 90-99% of cervical cancer (CxCa) cases. Although effective screening programs have reduced the incidence of CxCa in developed countries, they are often not well organized. Prophylactic vaccination against HPV seems to be a good strategy for the prevention of CxCa. However, because millions of women are already infected with HPV, therapeutic HPV vaccines need to be developed further to treat these women. This review discusses the actual perspectives on both HPV vaccines and immunotherapy worldwide. In addition, some of the perspectives in France are also briefly discussed.
Bermúdez-Humarán
Luis G
LG
Unité d'Ecologie et de Physiologie du Système Digestif, INRA, Domaine de Vilvert, 78352 Jouy-en-Josas cedex, France. luis.bermudez@jouy.inra.fr
Langella
Philippe
P
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D035843:Biomedical Research / Q000639:trends; D005260:Female; D005602:France / Q000453:epidemiology; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D015994:Incidence; D008875:Middle Aged; D027383:Papillomaviridae / Q000276:immunology*; D030361:Papillomavirus Infections / Q000453:epidemiology / Q000517:prevention & control* / Q000628:therapy*; D053918:Papillomavirus Vaccines / Q000276:immunology* / Q000627:therapeutic use*; D055815:Young Adult
D053918:Papillomavirus Vaccines